Adam J. Townsend - 11 Aug 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Role: Chief Commercial Officer
Signature: /s/ David Watson, attorney-in-fact for Adam Townsend
Issuer symbol: APLS
Transactions as of: 11 Aug 2022
Net transactions value: -$648,875
Form type: 4
Filing time: 12 Aug 2022, 17:01:25 UTC
Previous filing: 09 Aug 2022
Next filing: 16 Aug 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	APLS	Common Stock	Options Exercise	$188,625	+12,500	+29%	$15.09	55,407	11 Aug 2022	Direct	F1
transaction	APLS	Common Stock	Sale	$837,500	-12,500	-23%	$67.00	42,907	11 Aug 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	APLS	Stock Option (Right to Buy)	Options Exercise	$0	-12,500	-3.5%	$0.000000	340,000	11 Aug 2022	Common Stock	12,500	$15.09	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This is a scheduled exercise and sale form an established 10b5-1 plan.
F2	This represents a stock option granted 11/16/2018 that vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.